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with headache symptoms (16.97 o 0.54 vs. 5.38 o 0.39, p  0.0001). CM also missed 
more days due to illnesses other than headache than EM participants (13.66 o 1.98 
vs. 9.33 o 1.42, p  0.01). CM and EM reported working at about half of their full 
effectiveness with headache symptoms (p  0.05). CM reported experiencing more 
impairment on work ability or activity than EM (CM  31.1%, EM  24.4%), or 
requiring more bed rest (CM  33.5%, EM  26.2%) when experiencing severe 
headaches. CONCLUSIONS: Migraine adversely affected presenteeism and increased 
absenteeism of migraine sufferers, particularly among those with CM, who missed 
more days and worked more days with headache than EM.
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OBJECTIVES: To evaluate the direct and indirect costs of Parkinson´s Disease (PD) 
in a survey of ﬁve European countries and Russia. So far, cost-of-illness (COI) studies 
on PD have been conducted in some European countries only, none in Austria, Czech 
Republic, Portugal and Russia. The prevalence of PD in Europe varies between 115 
and 221 per 100,000, due to aging of population the number of persons affected is 
expected to double within the next 25 years. METHODS: Between 2003—2005 about 
100 patients of PD were recruited per study center. Clinical status (Hoehn & Yahr 
stage, Uniﬁed Parkinson’s Disease Rating Scale) was evaluated. Economic data were 
collected over a 6 months period using the “bottom-up” approach. Indirect costs were 
calculated by the human capital approach. Informal care was monetary valued. 
RESULTS: The total mean costs per patient ranged from a2620 to a9812 for the 6-
months observation period. Direct costs made about 60% to 70%, indirect costs made 
30% to 40% of total costs. Forty-seven percent to 92% of direct costs were on the 
account of the national health insurance systems. Patients’ co-payments constituted 
up to 14% of direct costs. Informal care generally was the prevalent form of care for 
PD patients. In half of the participating countries it was the major source of expendi-
ture. CONCLUSIONS: This is the ﬁrst observational study on the burden of PD across 
European countries and Russia. Costs of PD across Europe vary considerably. Reasons 
are multiple; differences in prices, health systems and traditions are some. PD repre-
sents a major burden on the individual, family, health services and society in Europe, 
especially in Eastern European countries. A major cost factor is the cost for care, which 
has enormous importance due to demographic development and extension of life 
expectancy.
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OBJECTIVES: To examine the economic impact of generic substitution of the anti-
epileptic drug (AED) Topiramate in Canada; and convert observed Canadian costs 
into the settings of France, Germany, Italy and the UK (UK). METHODS: Retrospec-
tive health claims from Québec’s provincial health plan (RAMQ) between January 
2006 and September 2008, and IMS Health data on European AED sales between 
1998 and 2008 were used. Patients with epilepsy (ICD-9: 345, 780.3, 780.39) and q2 
topiramate dispensings were selected. Patient-level health care utilization costs in 
Canada were calculated during mutually-exclusive periods of brand versus generic use 
of topiramate. Annualized Canadian health care costs were projected in each country 
(a2007/person-year) using Canadian rates, European prices and service-use ratios. 
Using market-level sales, topiramate utilization were forecasted for 12 months follow-
ing expected generic entry (September 2009-September 2010) using autoregressive and 
panel-data regression models. The impact of generic entry was projected for each 
country, stratiﬁed into its effect on market size, topiramate costs, and other health 
care costs. RESULTS: A total of 1164 patients (mean age: 39.8 years, 61.7% female) 
were observed for 2.6 years on average. Projected per-patient health care costs in G4 
European countries, excluding Topiramate, would be signiﬁcantly higher during 
generic-use periods (adjusted cost differences per person-year: a706 to a815, p  0.001 
for all comparisons) compared to brand-use periods. Assuming mandatory generic 
substitution for all patients, predicted system-wide increases in total adjusted health 
care costs would range from 3.5% (UK) to 24.4% (France) one year after generic 
entry. Increases in non-Topiramate health care costs (13.7% to 18.1%) would more 
than offset savings in incremental Topiramate brand costs (6.3% to 13.8%) in 
France, Italy, and the UK. CONCLUSIONS: The generic entry of Topiramate in 
Europe is projected to be associated with higher health care costs, representing a 
trade-off between reduced generic drug expenditures and increased health care 
costs.
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OBJECTIVES: investigated the impact of generic substitution of the branded antiepi-
leptic drug (AED) Topiramate (Topamax®) on medical service utilization and costs 
for patients with epilepsy in Germany. METHODS: Retrospective health claims from 
Québec’s provincial health plan (RAMQ) between January 2006 and September 2008 
were analyzed. Patients with epilepsy (ICD-9: 345, 780.3 or 780.39) and q2 topira-
mate (Topamax®) dispensings were selected. Patient-level health care utilization and 
costs in Canada were calculated during mutually-exclusive periods of brand versus 
generic use of topiramate. Annualized Canadian health care costs were converted into 
a German setting (a2007/person-year) by applying purchasing power parities, service-
use ratios and exchange rates. Using market-level sales, branded and generic topira-
mate utilization were forecasted for 12 months following expected generic entry 
(September 2009-September 2010) using autoregressive and panel-data regression 
models. Non-parametric bootstrap procedure was used to determine statistical signiﬁ-
cance for the cost measures. Budgetary consequences for sick funds, individual and 
private payers were assessed. RESULTS: After adjusting for covariates, periods of 
generic topiramate use were associated with signiﬁcant increases in pharmacy dispens-
ings (other AEDs: 6%, non-AEDs: 31%, p  0.001), a 17% increase in hospitaliza-
tions (p  0.015), and 21% longer lengths of hospital stays (p  0.001). Converted 
per-patient health care costs excluding topiramate were estimated to be signiﬁcantly 
higher for generic relative to brand periods in Germany (adjusted cost difference per 
person-year [95% CI]: a710 [a149–a1283]; p  0.001). Assuming mandatory generic 
substitution for all patients, predicted system-wide increase in total adjusted health 
care costs would be 23.2% one year after generic entry. This impact would be evenly 
distributed among payers. CONCLUSIONS: Generic entry of topiramate in Germany 
would represent a trade-off between reduced generic drug expenditures and increased 
health care costs due to higher AED and non-AED spending, as well as increased 
hospitalizations and outpatient visits. Increased total cost is expected to outweigh the 
beneﬁt of reduced drug costs.
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OBJECTIVES: In addition to medical treatment, deep brain stimulation (DBS) has 
become an alternative therapeutical option in advanced Parkinson’s disease, especially 
for motor complications such as dyskinesias or motor ﬂuctuations. High initial costs 
of surgery and subsequent time-consuming maintenance procedures may be traded off 
by long-term gains in quality of life (HrQoL) compared to conventional medication 
treatment. This leads to the question whether DBS is cost effective compared to best 
medical treatment. METHODS: We present a lifetime Markov model for Parkinson’s 
disease, comparing deep brain stimulation vs. best medical treatment and estimating 
the impact on health-related quality of life. HrQoL was measured by the EQ-5D and 
cost from the societal perspective of Germany. Both were discounted with 3% p.a.. 
Data on DBS efﬁcacy and adverse events were taken from clinical studies and pub-
lished reports or meta-analyses. Key assumptions on the surgery procedure and its 
durability, its impact on cost and HrQoL, mortality, prevalence of motor complica-
tions as well as stage transition probabilities and the discount rate were investigated 
by one- and two-way sensitivity analyses. RESULTS: The incremental cost effective-
ness ratio (ICER) for DBS was a42,183 per QALY gained. Incremental DBS costs were 
due to cost for surgery and subsequent battery change. HrQoL was improved and 
motor complications were reduced. The following variables had most impact in sen-
sitivity analyses: utility improvement under DBS, drug and surgery cost, progression 
rates, and discount rate leading to varying ICERs between 20,064 and a58,147/QALY 
(the latter due to extreme and unlikely parameter combinations). CONCLUSIONS: 
Based on our decision analysis using current guidelines, DBS is likely to be cost-
 effective compared with other well-accepted health care technologies. We suggest to 
adopt DBS for patients with high drug cost or severe motor complications.
PND18
COST-EFFECTIVENESS OF A NEW ABSORBABLE HYDROGEL FOR THE 
PREVENTION OF CSF LEAKS IN FRENCH HOSPITALS
Castanier JC1, Maunoury F2, Hédoux S3, Auffrand M3
1Independent Consultant in Health Economics, Lyon, France, 2STATESIA, Le Mans, France, 
3FRAVIMED, Lyon, France
OBJECTIVES: The objective was to demonstrate the cost-effectiveness of a new 
absorbable hydrogel used in craniotomies compared to the option “do nothing” in 
France. METHODS: A Markov model was fed with clinical data from Grotenhuis 
and al. (Surg. Neurol. 2005;64:490–3) and with cost data from the French cost data-
base (2006 data based on DRG (GHM) 01C04V craniotomy without complication 
and 01C04W craniotomy with complication). The model was run with three stages 
(T0: date of surgery; T1: 1-month follow-up; T2: 3-month follow-up) and three states 
